Company: ACHV
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0000950170-25-036831
Chunk: 143

Company: ACHIEVE LIFE SCIENCES, INC.
Filing Date: 2025-03-11
Form: 10-K
Item: Item 8
Chunk 143
---
 Proceeds from ATM, net of issuance costs [note 11[b]]

    —

    —

    1,330

    Proceeds from employee stock purchase plan [note 11[e]]

    178

    —

    126

    Taxes paid related to net share settlement of equity awards

    (114
    )

    (220
    )

    (47
    )

    Proceeds from the November 2022 private placement, net of issuance costs [note 11[b]]

    —

    (30
    )

    17,882

    Proceeds from May 2023 private placement, net of issuance costs [note 11[b]]

    —

    15,301

    —

    Proceeds from February 2024 registered direct offering, net of issuance costs [note 11[b]]

    56,076

    —

    —

    Repayment of 2023 SVB convertible term loan [note 7 and note 9]

    (18,109
    )

    —

    —

    Receipt of 2024 SVB convertible term loan less transaction costs [note 7 and note 9]

    9,814

    —

    —

    Net cash provided by financing activities

    48,527

    15,278

    19,315

    Investing Activities:

    Purchase of property and equipment

    —

    (21
    )

    —

    Purchase of investments

    (47,887
    )

    —

    —

    Maturities of investments

    26,307

    —

    —

    Net cash provided by (used in) investing activities

    (21,580
    )

    (21
    )

    —

    Effect of exchange rate changes on cash

    —

    (3
    )

    3

    Net increase (decrease) in cash, cash equivalents and restricted cash

    (2,823
    )

    (9,225
    )

    (18,251
    )

    Cash, cash equivalents and restricted cash at beginning of year

    15,596

    24,821

    43,072

    Cash, cash equivalents and restricted cash at end of year
     
    $
    12,773

    $
    15,596

    $
    24,821

See accompanying notes.

71

Achieve Life Sciences, Inc.